Washington, DC - The U.S. Food and Drug Administration Thursday expanded the approval of the MiniMed 670G hybrid closed looped system, a diabetes management device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses with little or no input from the user, to include individuals aged 7 to 13 with type 1 diabetes. The FDA originally approved this device in September 2017 for use in patients 14 years of age and older with type 1 diabetes.

Dallas, Texas - Flavor additives used in electronic cigarettes and related tobacco products could impair blood vessel function and may be an early indicator of heart damage, according to new laboratory research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.

Washington, DC - The National Institutes of Health plans to end funding to the Moderate Alcohol and Cardiovascular Health (MACH) trial. The decision is based on concerns about the study design that cast doubt on its ultimate credibility.  This includes whether the study would effectively address other significant consequences of moderate alcohol intake, such as cancer.  National Institute of Alcohol Abuse and Alcoholism (NIAAA) funding for the MACH trial will end within the next few months following completion of an orderly closeout.

Dallas, Texas - More people than ever are able to resume working after a heart attack, but those working less or unable to work reported lower quality of life with increased depression and difficulty affording their medication, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

West Lafayette, Indiana - Cells have traditionally been categorized into different types, such as T-cells and B-cells, based on observable features. But new research published in Nature Communications shows cells are far more complex.